Fluoxetine, a commonly used antidepressant, has been documented to lower serum levels of inflammatory markers including IL‐1β, IL‐6, and TNF‐α (Mojiri‐Forushani et al., 2023), suggesting that inhibition of inflammation could attenuate depression. This evidence concerns the gene IL1B and major depressive disorder.